Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

Bristol-Myers Squibb (BMS) building

BMS drops antidepressant in phase IIb

Liafensine no better than Lilly’s Cymbalta

- PMLiVE

Astellas poaches new oncology head from Takeda

Claire Thom is named senior VP of global oncology development

- PMLiVE

Amgen buys US rights to Servier’s Procoralan

Also obtains option to develop S38844 while Servier has option to commercialise omecamtiv mecarbil in Europe

- PMLiVE

The brand model – time for change?

Is it time to tune more into emotional decision-making, letting go of a strict formulaic approach?

- PMLiVE

Sharing ideas to improve care for cancer patients – part 2

Quality in Care (QiC) Excellence in Oncology is a tri-partite programme recognising, rewarding and disseminating good practice in cancer management, education and patient care throughout the UK.

- PMLiVE

Sharing ideas to improve care for cancer patients – part 1

Quality in Care (QiC) Excellence in Oncology is a tri-partite programme recognising, rewarding and disseminating good practice in cancer management, education and patient care throughout the UK.

- PMLiVE

Avanir to co-promote Merck’s diabetes drugs in the US

Will market Januvia and Janumet to care homes

- PMLiVE

ViiV gets US nod for HIV drug dolutegravir

GSK and Pfizer joint venture on course for first drug launch

UK flag

UK sets aside £124m for health research projects

National Institute for Health Research to aims to revolutionise care

InnoPharma appoints Deborah DuFresne as VP

Will head strategic portfolio selection and management

- PMLiVE

Vical’s cancer immunotherapy fails in late-stage trial

Allovectin no better than standard chemotherapy

Pharma deals during July 2013

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links